Targeted protein degradation is an emerging therapeutic modality based on the use of molecules called degraders with the potential to tackle targets that have historically been highly challenging to target with conventional small molecules. Application of targeted protein degradation embraces experimental procedures based on engineered systems for ligand-induced protein degradation, computational and medical chemists, and rational design of novel therapeutic approaches.

This meeting will attract the interest of both basic and translational researchers, offering the opportunity to dive into the biggest challenges in early discovery and preclinical stages of targeted protein degradation. The attendances will learn how to identify new targets, discover novel ligands, and move them from early discovery to potential drug candidate. Interaction with speakers, including experts from academia as well as pharma, is favored to generate discussion, and foster collaboration in the field of protein degradation.

Referents

Scientific Committee

051-6366760

katia.scotlandi@ior.it

Scotlandi Katia, MSc

Head

Laboratory of Experimental Oncology

051-6366378

caterina.mancarella@ior.it

Mancarella Caterina, PhD

Researcher

Laboratory of Experimental Oncology